KRRO — Korro Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703647 ·
Last close
$13.07
Market Cap
$192.46M
52W High
$15.55
52W Low
$9.76
ADV30
126,299
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -20,110,000 | -18,916,000 | 163,446,000 | 24,905,000 | 60,220,000 |
| Mar 2026 | 0 | — | -20,436,000 | -19,625,000 | 183,622,000 | 61,697,000 | 63,989,000 |
| Dec 2025 | 1,292,000 | — | -15,883,000 | -50,042,000 | 113,506,000 | 21,824,000 | 62,067,000 |
| Sep 2025 | 1,090,000 | — | -19,237,000 | -18,061,000 | 161,550,000 | 24,155,000 | 62,518,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-67,948,000
Investing CF
$-27,629,000
Financing CF
$85,803,000
CapEx
$-317,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.42
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-422,387,000
Inventory
—
Receivables
$0
ST Investments
$90,131,000
EBIT TTM
$-75,666,000
Pretax Income TTM
$-105,805,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,382,000
EBITDA
$-74,326,000
Free Cash Flow
$-41,390,124
Enterprise Value
$119,641,192
Total Cash
$115,036,000
Total Debt
$42,213,000
Shares Out
14,725,646
Trailing EPS
$-9.83
Book Value
$7.02
ROE
-97.7%
ROA
-28.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,392,000 | -87,342,000 | -117,260,000 | 113,506,000 | 62,067,000 | — | -78,561,000 |
| Dec 2024 | 2,271,000 | -91,910,000 | -83,581,000 | 226,240,000 | 65,825,000 | — | -60,074,000 |
| Dec 2023 | 0 | -84,534,000 | -81,172,000 | 221,663,000 | 51,752,000 | — | -67,283,000 |
| Dec 2022 | 0 | -58,998,000 | -58,032,000 | 73,742,000 | 172,773,000 | — | -53,645,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.46
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $13.63 · call volume: 28 · put volume: 0
Expected Move to 2027-01-15:
±$5.60
(41.09%) —
implied range
$8.03 –
$19.23
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORMP | ORAMED PHARMACEUTICALS INC. | $197.26M | $4.82 | — |
| NKTX | Nkarta, Inc. | $185.51M | $2.59 | — |
| MSLE | Satellos Bioscience Inc. | $200.92M | $9.47 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $206.76M | $10.69 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $178.86M | $1.68 | — |
News headlines (Yahoo Finance, 1h cache)
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 11:00 · Yahoo
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-08 16:00 · Yahoo
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
2026-06-19 12:06 · Yahoo
One Korro Bio Insider Raised Stake By 19% In Previous Year
2026-06-11 11:38 · Yahoo
Korro to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-27 11:00 · Yahoo
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2026-05-19 11:00 · Yahoo
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 20:05 · Yahoo
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 11:00 · Yahoo
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
2026-04-28 16:00 · Yahoo
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development
2026-06-10 12:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.